{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T19:01:42Z","timestamp":1782586902075,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>An increasing amount of evidence supports the relevance of epithelium across the wide spectrum of asthma pathobiology. On a clinical ground tezepelumab, selectively binding TSLP, a major epithelial cytokine, has demonstrated to be effective in asthma patients regardless their specific phenotype. In order to avoid the risk of considering tezepelumab as a not-specific option, the present perspective aims to sketch the tezepelumab best eligible patient profile and to propose some hallmarks of epithelial-driven disease by reviewing the published evidence on the drug mechanism of action and efficacy data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Main body<\/jats:title>\n                <jats:p>Although it cannot rely on standardised or exclusive \u201cmarkers\u201d, the relationship between environment and poor asthma control might suggest a major relevance of the epithelial barrier dysfunction. In that light, allergy and asthma exacerbations concomitant with specific exposures (pathogens, pollutants, chemicals), as well as increased susceptibility to infections can be considered as the hallmark of an impaired epithelial immune response. Tezepelumab is effective in allergic patients, being able to reduce asthma exacerbations precipitated by the exposure to seasonal or perennial aeroallergens, including fungi. In addition, tezepelumab reduced the incidence of co-occurring respiratory illness and asthma exacerbations. In terms of inflammation, epithelial immune response has been related to an impaired mucus hypersecretion and plugging. A placebo-controlled trial demonstrated a significant reduction of mucus plugging in treated patient. Airways hyperreactivity (AHR), airways obstruction and remodelling have been described as an expression of epithelial orchestrated immunological activation. Of note, a significantly higher incidence of mannitol negative test in patients treated with tezepelumab when compared to placebo group has been observed. In addition, A 130 mL improvement in pre-BD FEV1 has been described in patients assuming Tezepelumab. The above-mentioned data suggest that bronchial reversibility and AHR can be considered \u201cfunctional biomarkers\u201d supporting patients\u2019 phenotyping and the identification of tezepelumab best responders.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Integrating \u201cfunctional biomarkers\u201d to the inflammatory ones and a better characterization of asthma exacerbations might pave the way to a different and more transversal phenotyping, which overcomes the \u201crestrictive\u201d labels including T2 high, allergic\/atopic or T2 low asthma. Precisely defining the disease characteristics and potential targets for a better control even in tezepelumab eligible subjects is essential to avoid the block buster temptation and optimize the personalized medicine approach according to each patient\u2019s individuality.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-024-02998-6","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T19:02:04Z","timestamp":1728500524000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Tezepelumab for severe asthma: elevating current practice to recognize epithelial driven profiles"],"prefix":"10.1186","volume":"25","author":[{"given":"Marco","family":"Caminati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vatrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Rogliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Carpagnano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Spanevello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Senna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"key":"2998_CR1","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1111\/all.16092","volume":"79","author":"R Berni Canani","year":"2024","unstructured":"Berni Canani R, Caminati M, Carucci L, Eguiluz-Gracia I. Skin, gut, and lung barrier: physiological interface and target of intervention for preventing and treating allergic diseases. Allergy. 2024;79:1485\u2013500.","journal-title":"Allergy"},{"key":"2998_CR2","doi-asserted-by":"publisher","first-page":"1258859","DOI":"10.3389\/fcell.2024.1258859","volume":"12","author":"R L\u00f3pez-Posadas","year":"2024","unstructured":"L\u00f3pez-Posadas R, Bagley DC, Pardo-Pastor C, Ortiz-Zapater E. The epithelium takes the stage in asthma and inflammatory bowel diseases. Front Cell Dev Biol. 2024;12:1258859.","journal-title":"Front Cell Dev Biol"},{"key":"2998_CR3","doi-asserted-by":"crossref","unstructured":"Carr TF, Moore WC, Kraft M, Brusselle G, Castro M, Chupp GL et al. Efficacy of Tezepelumab in patients with severe, uncontrolled asthma across multiple clinically relevant Subgroups in the NAVIGATOR Study. Adv Ther. 2024 Jul;41(7):2978\u20132990.","DOI":"10.1007\/s12325-024-02889-8"},{"key":"2998_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/NEJMra2032506","volume":"386","author":"GG Brusselle","year":"2022","unstructured":"Brusselle GG, Koppelman GH. Biologic therapies for severe asthma. N Engl J Med. 2022;386:157\u201371.","journal-title":"N Engl J Med"},{"key":"2998_CR5","first-page":"1","volume":"22","author":"JC Miralles-L\u00f3pez","year":"2024","unstructured":"Miralles-L\u00f3pez JC, Antol\u00edn-Am\u00e9rigo D, Garc\u00eda-Moguel I, Dom\u00ednguez-Ortega J, Delgado-Romero J, Quirce S. Positioning of Tezepelumab in severe asthma. J Investig Allergol Clin Immunol. 2024;22:34:1\u201311.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2998_CR6","unstructured":"Europena Medical Agency. Tezepelumab EPAR. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tezspire. Accessed 30 June 2024."},{"key":"2998_CR7","unstructured":"Food. June and drug administration: Tezepelumab. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-maintenance-treatment-severe-asthma. Accessed 30 2024."},{"key":"2998_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02770903.2024.2361783","volume":"28","author":"MA Pasha","year":"2024","unstructured":"Pasha MA, Hopp R, Habib N, Tang D. Biomarkers in Asthma, potential for therapeutic intervention. J Asthma. 2024;28:1\u201330.","journal-title":"J Asthma"},{"key":"2998_CR9","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/all.15986","volume":"79","author":"M Caminati","year":"2024","unstructured":"Caminati M, Buhl R, Corren J, Hanania NA, Kim H, Korn S, et al. Tezepelumab in patients with allergic and eosinophilic asthma. Allergy. 2024;79:1134\u201345.","journal-title":"Allergy"},{"key":"2998_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1164\/rccm.202210-2005OC","volume":"208","author":"J Corren","year":"2023","unstructured":"Corren J, Menzies-Gow A, Chupp G, Israel E, Korn S, Cook B, et al. Efficacy of Tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208:13\u201324.","journal-title":"Am J Respir Crit Care Med"},{"key":"2998_CR11","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.anai.2023.08.015","volume":"131","author":"ID Pavord","year":"2023","unstructured":"Pavord ID, HoyteCLF, Lindsley AW, Ambrose CS, Spahn JD, Roseti SL, et al. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR). Ann Allergy Asthma Immunol. 2023;131:587\u2013e5973.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2998_CR12","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/ACI.0000000000000971","volume":"24","author":"M Maule","year":"2024","unstructured":"Maule M, Vitte J, Ambrosani F, Caminati M. Epidemiology of the relationship between allergic bronchopulmonary aspergillosis and asthma. Curr Opin Allergy Clin Immunol. 2024;24:102\u20138.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"2998_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.11.320","author":"J Corren","year":"2024","unstructured":"Corren J, Mathur SK, Carr TF, Wardlaw AJ, Caminati M, Martin N, et al. Efficacy of Tezepelumab in patients with severe, uncontrolled asthma and fungal sensitization. J Allergy Clin Immunol. 2024. https:\/\/doi.org\/10.1016\/j.jaci.2023.11.320. 153,2, supplement, ab97.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2998_CR14","doi-asserted-by":"publisher","first-page":"2301397","DOI":"10.1183\/13993003.01397-2023","volume":"63","author":"RJ Russell","year":"2024","unstructured":"Russell RJ, Boulet LP, Brightling CE, Pavord ID, Porsbjerg C, Dorscheid D, et al. The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma. Eur Respir J. 2024;63(4):2301397.","journal-title":"Eur Respir J"},{"key":"2998_CR15","unstructured":"Feleszko W, Caminati M, Johnston SL, Clarke D, Gern JE, Martin NL et al. The effect of tezepelumab treatment on the incidence of asthma exacerbations co-occurring with acute respiratory illnesses attributed to infections: results from a pooled analysis of the PATHWAY and NAVIGATOR studies. Presented at the annual congress of the European Academy of Allergy and Clinical Immunology (EAACI), 31 May \u2013 3 June 2024, Valencia, Spain. https:\/\/eaaci.org\/agenda\/eaaci-congress-2024\/sessions\/flash-talks-on-asthma\/the-effect-of-tezepelumab-treatment-on-the-incidence-of-asthma-exacerbations-co-occurring-with-acute-respiratory-illnesses-attributed-to-infections-results-from-a-pooled-analysis-of-the-pathway-and-n\/"},{"key":"2998_CR16","first-page":"EVIDoa2300135","volume":"2","author":"LH Nordenmark","year":"2023","unstructured":"Nordenmark LH, Hellqvist \u00c5, Emson C, Diver S, Porsbjerg C, Griffiths JM, et al. Tezepelumab and mucus plugs in patients with moderate-to-severe asthma. NEJM. 2023;2:EVIDoa2300135.","journal-title":"NEJM"},{"key":"2998_CR17","doi-asserted-by":"publisher","first-page":"2101296","DOI":"10.1183\/13993003.01296-2021","volume":"59","author":"A Sverrild","year":"2021","unstructured":"Sverrild A, Hansen S, Hvidtfeldt M, Clausson C-M, Cozzolino O, Cerps S, et al. The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM). Eur Respir J. 2021;59:2101296.","journal-title":"Eur Respir J"},{"issue":"11","key":"2998_CR18","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","volume":"9","author":"S Diver","year":"2021","unstructured":"Diver S, Khalfaoui L, Emson C, Wenzel SE, Menzies-Gow A, Wechsler ME, et al. CASCADE study investigators. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299\u2013312.","journal-title":"Lancet Respir Med"},{"key":"2998_CR19","doi-asserted-by":"publisher","first-page":"190137","DOI":"10.1183\/16000617.0137-2019","volume":"29","author":"M Bonini","year":"2020","unstructured":"Bonini M, Di Paolo M, Bagnasco D, Baiardini I, Braido F, Caminati M, et al. Minimal clinically important difference for asthma endpoints: an expert consensus report. Eur Respir Rev. 2020;29:190137.","journal-title":"Eur Respir Rev"},{"key":"2998_CR20","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","volume":"384","author":"A Menzies-Gow","year":"2021","unstructured":"Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384:1800\u20139.","journal-title":"N Engl J Med"},{"issue":"11","key":"2998_CR21","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1007\/s12325-023-02659-y","volume":"40","author":"A Menzies-Gow","year":"2023","unstructured":"Menzies-Gow A, Ambrose CS, Colice G, Hunter G, Cook B, Molfino NA, et al. Effect of Tezepelumab on lung function in patients with severe, uncontrolled asthma in the phase 3 NAVIGATOR Study. Adv Ther. 2023;40(11):4957\u201371.","journal-title":"Adv Ther"},{"key":"2998_CR22","doi-asserted-by":"publisher","first-page":"105947","DOI":"10.1016\/j.rmed.2020.105947","volume":"166","author":"GW Canonica","year":"2020","unstructured":"Canonica GW, Malvezzi L, Blasi F, Paggiaro P, Mantero M, Senna G, et al. Severe Asthma Network Italy (SANI). Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: evidences from the severe Asthma Network Italy (SANI) registry. Respir Med. 2020;166:105947.","journal-title":"Respir Med"},{"key":"2998_CR23","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jaci.2022.02.016","volume":"149","author":"A Kato","year":"2022","unstructured":"Kato A, Schleimer RP, Bleier BS. Mechanisms and pathogenesis of chronic rhinosinusitis. J Allergy Clin Immunol. 2022;149:1491\u2013503.","journal-title":"J Allergy Clin Immunol"},{"key":"2998_CR24","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2147\/JAA.S413064","volume":"16","author":"TM Laidlaw","year":"2023","unstructured":"Laidlaw TM, Menzies-Gow A, Caveney S, Han JK, Martin N, srael E, et al. Tezepelumab Efficacy in patients with severe, uncontrolled asthma with Comorbid nasal polyps in NAVIGATOR. J Asthma Allergy. 2023;16:915\u201332.","journal-title":"J Asthma Allergy"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-024-02998-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-024-02998-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-024-02998-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T07:05:14Z","timestamp":1728543914000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-024-02998-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2998"],"URL":"https:\/\/doi.org\/10.1186\/s12931-024-02998-6","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,9]]},"assertion":[{"value":"12 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"367"}}